Skip to main content
PMC home page
Proceedings of the AMIA Annual Fall Symposium logoLink to Proceedings of the AMIA Annual Fall Symposium
. 1997:273–277.

Assessing the value of newer pharmacologic agents in non-ST elevation patients: a decision support system application.

E L Eisenstein 1, E D Peterson 1, J G Jollis 1, B E Tardiff 1, R M Califf 1, J D Knight 1, D B Mark 1
PMCID: PMC2233333  PMID: 9357631

Abstract

Newer pharmacologic agents have demonstrated significant clinical and economic benefit in high-risk percutaneous transluminal coronary angioplasty (PTCA) patients. However, the higher costs of these agents may prohibit their use in lower-risk coronary artery disease (CAD) populations. We developed a decision support system (DSS) to determine the level of clinical effectiveness these newer agents must exhibit to be either cost-neutral or cost-effective in non-ST elevation patients. Our DSS evaluated six month cumulative costs, increased years of life saved (YOLS), and lifetime cost-effectiveness. We found that these therapies can cost as much as $1500 and be cost-neutral at six months if they reduce the composite endpoint of death, myocardial infarction (MI), or revascularization by 15%, and they may cost as much as $3000 and be cost-effective if they reduce this endpoint by 10%.

Full text

PDF
273

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993 Sep 2;329(10):673–682. doi: 10.1056/NEJM199309023291001. [DOI] [PubMed] [Google Scholar]
  2. Beck J. R., Pauker S. G. The Markov process in medical prognosis. Med Decis Making. 1983;3(4):419–458. doi: 10.1177/0272989X8300300403. [DOI] [PubMed] [Google Scholar]
  3. Braunwald E., Cannon C. P., McCabe C. H. An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point. Circulation. 1992 Aug;86(2):683–687. doi: 10.1161/01.cir.86.2.683. [DOI] [PubMed] [Google Scholar]
  4. Califf R. M., Harrelson-Woodlief L., Topol E. J. Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation. 1990 Nov;82(5):1847–1853. doi: 10.1161/01.cir.82.5.1847. [DOI] [PubMed] [Google Scholar]
  5. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation. 1994 Apr;89(4):1545–1556. doi: 10.1161/01.cir.89.4.1545. [DOI] [PubMed] [Google Scholar]
  6. Ferguson J. J., 3rd EPILOG and CAPTURE trials halted because of positive interim results. Circulation. 1996 Feb 15;93(4):637–637. doi: 10.1161/01.cir.93.4.637. [DOI] [PubMed] [Google Scholar]
  7. Mark D. B., Hlatky M. A., Califf R. M., Naylor C. D., Lee K. L., Armstrong P. W., Barbash G., White H., Simoons M. L., Nelson C. L. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995 May 25;332(21):1418–1424. doi: 10.1056/NEJM199505253322106. [DOI] [PubMed] [Google Scholar]
  8. Mark D. B., Talley J. D., Topol E. J., Bowman L., Lam L. C., Anderson K. M., Jollis J. G., Cleman M. W., Lee K. L., Aversano T. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation. 1996 Aug 15;94(4):629–635. doi: 10.1161/01.cir.94.4.629. [DOI] [PubMed] [Google Scholar]
  9. Sonnenberg F. A., Beck J. R. Markov models in medical decision making: a practical guide. Med Decis Making. 1993 Oct-Dec;13(4):322–338. doi: 10.1177/0272989X9301300409. [DOI] [PubMed] [Google Scholar]
  10. Topol E. J., Califf R. M., Weisman H. F., Ellis S. G., Tcheng J. E., Worley S., Ivanhoe R., George B. S., Fintel D., Weston M. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet. 1994 Apr 9;343(8902):881–886. doi: 10.1016/s0140-6736(94)90007-8. [DOI] [PubMed] [Google Scholar]
  11. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994 Apr 7;330(14):956–961. doi: 10.1056/NEJM199404073301402. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the AMIA Annual Fall Symposium are provided here courtesy of American Medical Informatics Association

RESOURCES